Advertisement

Canadian Journal of Public Health

, Volume 99, Issue 2, pp 114–116 | Cite as

The Human Papillomavirus Vaccine in Canada

  • Shaun K. MorrisEmail author
  • Claire K. Nguyen
Commentary
  • 2 Downloads

Abstract

Clinical studies have shown the human papillomavirus (HPV) vaccines to be very effective at preventing persistent infection by vaccine serotypes. The development of these new vaccines heralds a new era in cancer prevention. Gardasil, Merck’s quadravalent HPV vaccine, has recently been licensed in Canada for women aged 9 to 26 years of age. It necessitates that health professionals become familiar with the vaccine, the evidence supporting its effectiveness and issues related to vaccine strategy, cost effectiveness, and remaining research questions. The vaccine is recommended in Canada for females aged 9 to 13 years and should also be offered to females aged 14 to 26 years. Ongoing research will determine the duration of protection conferred by the vaccine, and the potential need for booster doses. In conjunction with continued screening programs, the HPV vaccine offers the potential to dramatically reduce the burden of cervical cancer in Canada, and to do so in a cost-effective manner.

Key words

Human papillomavirus cervical neoplasms vaccines public health Canada 

Résumé

Des études cliniques ont montré que les vaccins contre le virus du papillome humain (VPH) sont très efficaces pour prévenir les infections persistantes par les sérotypes vaccinaux. La mise au point de ces vaccins annonce une ère nouvelle pour la prévention du cancer. Gardasil, le vaccin quadrivalent anti-VPH de Merck, a récemment été homologué au Canada pour les filles et les femmes de 9 à 26 ans. Il faut cependant que les professionnels de la santé se familiarisent avec le vaccin, les preuves de son efficacité, la stratégie de vaccination, le rapport coût-efficacité et les questions de recherche non résolues. Au Canada, le vaccin est recommandé pour les filles de 9 à 13 ans et devrait aussi être offert aux filles et aux femmes de 14 à 26 ans. Des recherches en cours permettront de déterminer la durée de la protection conférée par le vaccin et les doses de rappel nécessaires, le cas échéant. Utilisé conjointement avec les programmes de détection en cours, le vaccin anti-VPH présente la possibilité de réduire considérablement le fardeau du cancer du col utérin au Canada, et de le faire de façon économiquement rentable.

Mots clés

virus du papillome humain néoplasmes cervicaux vaccins santé publique Canada 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Monsonego J, Bosch FX, Coursaget P, Cox JT, Franco E, Frazer I, et al. Cervical cancer control, priorities and new directions. Int J Cancer 2004;108(3):329–33.CrossRefGoogle Scholar
  2. 2.
    Spence AR, Franco EL, Ferenczy A. The role of human papillomaviruses in cancer: Evidence to date. Am J Cancer 2005;4(1):49–64.CrossRefGoogle Scholar
  3. 3.
    Cohen J. High hopes and dilemmas for a cervical cancer vaccine. Science 2005;308:618–21.CrossRefGoogle Scholar
  4. 4.
    Hernandez BY, McDuffie K, Zhu X, Wilkens LR, Killeen J, Kessel B, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev 2005;11(1):2550–56.CrossRefGoogle Scholar
  5. 5.
    van der Snoek EM, Niesters HG, Mulder PG, van Doornum GJ, Osterhaus AD, van der Meijden WI. Human papillomavirus infection in men who have sex with men participating in a Dutch gay-cohort study. Sex Transm Dis 2003;30(8):639–44.CrossRefGoogle Scholar
  6. 6.
    Leung AK, Kellner JD, Davies HD. Genital infection with human papillomavirus in adolescents. Adv Ther 2005;22(3):187–97.CrossRefGoogle Scholar
  7. 7.
    Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, et al. The natural history of human papillomavirus infection as measured by repeat DNA testing in adolescent and young women. J Pediatr 1998;132:277–84.CrossRefGoogle Scholar
  8. 8.
    Public Health Agency of Canada. STI Epi Update. Available online at: https://doi.org/www.phac-aspc.gc.ca/publicat/epiu-aepi/std-mts/hpv_e.html (Accessed March 2, 2006).
  9. 9.
    Programmatic Guidelines for Screening for Cancer of the Cervix in Canada. Society of Gynecologic Oncologists of Canada and Health Canada, 1998. Available online at: https://doi.org/www.phac-aspc.gc.ca/ccdpc-cpcmc/cc-ccu/pdf/screening.pdf (Accessed March 3, 2006).
  10. 10.
    Canadian Cancer Society. Canadian Cancer Statistics 2005. Available online at: https://doi.org/www.ncic.cancer.ca/vgn/images/portal/cit_867511 l4/60/42/393678947ncic_2005stats_en. pdf (Accessed March 2, 2006).Google Scholar
  11. 11.
    Public Health Agency of Canada. Human Papillomavirus (HPV) Prevention and HPV Vaccine: Questions and Answers. Available online at: https://doi.org/www.phac-aspc.gc.ca/std-mts/hpv-vph/hpv-vph-vaccine_e.html (Accessed November 15, 2006).Google Scholar
  12. 12.
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–51.CrossRefGoogle Scholar
  13. 13.
    Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2006;107(1):l8-27.CrossRefGoogle Scholar
  14. 14.
    Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebocontrolled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271–78.CrossRefGoogle Scholar
  15. 15.
    Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillmavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004;364(9447):1757–65.CrossRefGoogle Scholar
  16. 16.
    Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 2006;367(9518):1247–55.CrossRefGoogle Scholar
  17. 17.
    The National Advisory Committee on Immunization (NACI). Statement on Human Papillomavirus Vaccine. Canada Communicable Disease Report 2007;33 ACS-2:1–32.Google Scholar
  18. 18.
    Scheifele D. Universal childhood hepatitis B vaccination: Infants vs. preadolescents, the Canadian perspective. Pediatr Lnfect Dis J 1998;17(7 Suppl):S35–S37.CrossRefGoogle Scholar
  19. 19.
    Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9(1):37–48.CrossRefGoogle Scholar
  20. 20.
    Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10(11):1915–23.CrossRefGoogle Scholar
  21. 21.
    Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Lnst 2004;96(8):604–15.CrossRefGoogle Scholar
  22. 22.
    Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290(6):781–89.CrossRefGoogle Scholar
  23. 23.
    Brabin L, Roberts SA, Farzaneh F, Kitchener HC. Future acceptance of adolescent human papillomavirus vaccination: A survey of parental attitudes. Vaccine 2006;24(16):3087–94.CrossRefGoogle Scholar
  24. 24.
    Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: Promise and problems of the magic bullets for prevention and control. Sex Transm Dis 2000;1:49–52.CrossRefGoogle Scholar
  25. 25.
    Humiston SG, Rosenthal SL. Challenges to vaccinating adolescents: Vaccine implementation issues. Pediatr Lnfect Dis J 2005;24(6 Suppl.):S134–40.CrossRefGoogle Scholar
  26. 26.
    Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10 to 15 year old adolescents. J Low Genit Tract Dis 2004;8(3):188–94.CrossRefGoogle Scholar
  27. 27.
    Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Psychosocial aspects of vaccine acceptability. Vaccine 2006;24(Suppl 3):S201–9.CrossRefGoogle Scholar
  28. 28.
    The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915–27.CrossRefGoogle Scholar
  29. 29.
    Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95(11):1459–66.CrossRefGoogle Scholar
  30. 30.
    World Health Organization. Cervical Cancer Screening in Developing Countries. Available online at: https://doi.org/whqlibdoc.who.int/publications/2002/9241545720.pdf (Accessed November 15, 2006)Google Scholar
  31. 31.
    Lavanchy DJ. Hepatitis B virus epidemiology. disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97–107.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2008

Authors and Affiliations

  1. 1.Division of Infectious DiseasesThe Hospital for Sick Children and The University of TorontoTorontoCanada
  2. 2.Registered NurseMount Sinai HospitalTorontoCanada

Personalised recommendations